Pharmaceuticals

Budesonide Inhaler Market to Reach $9.47 Billion by 2029, Growing at a CAGR of 8.3%

November 10, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Global Market Value Of The Budesonide Inhaler Industry In 2025?

The budesonide inhaler market size has seen significant expansion recently. It is anticipated to increase from $6.37 billion in 2024 to $6.88 billion in 2025, at a compound annual growth rate (CAGR) of 8.0%. This growth observed in past periods is attributable to heightened awareness of inhalation therapies, greater acceptance of corticosteroid treatments, an increase in air pollution levels leading to respiratory problems, growing demand for minimally invasive drug delivery, and an increasing focus on healthcare solutions provided at home.

The budesonide inhaler market is projected to experience substantial expansion over the upcoming years, reaching “$9.47 billion by 2029, with an anticipated compound annual growth rate (CAGR) of 8.3%.” This predicted growth stems from several factors, including heightened investment in the development of respiratory drugs, an increasing need for customized medicine within respiratory care, the growing adoption of telemedicine and electronic prescriptions, greater understanding of early diagnosis and treatment, and a rising inclination towards combination inhaler treatments. Key developments expected during this period involve sophisticated formulation methods for improved drug delivery, advancements in smart inhalers featuring digital tracking capabilities, the incorporation of AI and IoT into respiratory health management, progress in patient-focused drug designs, and the integration of mobile applications for monitoring treatment adherence.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24181&type=smp

What Are The Emerging Market Drivers Creating New Opportunities In The Budesonide Inhaler Industry?

The increasing occurrence of respiratory disorders is anticipated to drive the expansion of the budesonide inhaler market moving forward. Respiratory disorders are medical conditions that impact the lungs and airways, making breathing difficult and often resulting in symptoms such as coughing, wheezing, and shortness of breath. These conditions include asthma, chronic obstructive pulmonary disease (COPD), pneumonia, bronchitis, and various lung infections. The surge in respiratory disorders is largely due to increasing air pollution, which heightens exposure to harmful pollutants that irritate the airways and compromise lung function. Budesonide inhalers manage respiratory disorders by delivering anti-inflammatory medication directly to the lungs, providing sustained control. Their compact form factor makes them convenient to use and carry, helping to reduce flare-ups and improve overall respiratory health. For instance, in December 2023, data from the Australian Bureau of Statistics, an Australia-based government agency, showed that the prevalence of chronic obstructive pulmonary disease (COPD) increased from 2.4% in 2021 to 2.5% in 2022. Thus, the growing prevalence of respiratory disorders is fueling the growth of the budesonide inhaler market.

How Is The Budesonide Inhaler Market Classified Into Different Segments?

The budesonide inhaler market covered in this report is segmented –

1) By Product Type: Metered-Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs), Nebulizers, Combination Inhalers

2) By Dosage Form: Aerosols, Dry Powder, Suspension, Spray

3) By Indication: Asthma, Chronic Obstructive Pulmonary Disease, Allergic Rhinitis

4) By End User: Hospitals, Outpatient Clinics, Homecare Settings, Pharmacies

Subsegments:

1) Metered-Dose Inhalers: Pressurized Metered-Dose Inhalers, Breath-Actuated Metered-Dose Inhalers, Spacer-Compatible Metered-Dose Inhalers, Hydrofluoroalkane Propellant-Based Metered-Dose Inhalers

2) Dry Powder Inhalers: Single-Dose Dry Powder Inhalers, Multi-Dose Dry Powder Inhalers, Capsule-Based Dry Powder Inhalers, Reservoir-Based Dry Powder Inhalers

3) Nebulizers: Jet Nebulizers, Ultrasonic Nebulizers, Mesh Nebulizers, Homecare Nebulizers, Hospital-Use Nebulizers

4) Combination Inhalers: Budesonide And Formoterol Inhalers, Budesonide And Salmeterol Inhalers, Budesonide, Glycopyrrolate, And Formoterol Inhalers, Budesonide And Vilanterol Inhalers

Which Competitive Trends Are Defining The Budesonide Inhaler Market Structure?

Key companies within the budesonide inhaler market are concentrating on developing advanced products, such as generic alternatives, to boost affordability and broaden access to treatments for respiratory ailments. Generic inhalation products are non-branded forms of inhaled medications that deliver the identical active ingredients, dosage, and therapeutic results as their branded counterparts, typically at a reduced cost. For example, in July 2023, Viatris Inc., a US-based pharmaceutical company, collaborated with Kindeva Drug Delivery L.P., a US-based pharmaceutical manufacturing company, to introduce Breyna (budesonide and formoterol fumarate dihydrate) inhalation aerosol, which is the first Food and Drug Administration (FDA), a US-based federal agency-approved generic version of Symbicort. This drug-device combination is formulated to treat asthma and chronic obstructive pulmonary disease (COPD), functioning by budesonide reducing inflammation in the airways, while formoterol relaxes the muscles around the airways, consequently offering patients a more economical choice.

Who Are The Prominent Global Companies Shaping The Budesonide Inhaler Market?

Major companies operating in the budesonide inhaler market are AstraZeneca plc, GSK plc, Takeda Pharmaceutical Company Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Sandoz International GmbH, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Synmosa Biopharma Corporation, Chiesi Farmaceutici S.p.A., Aurobindo Pharma Limited, Cipla Limited, Hikma Pharmaceuticals PLC, Lupin Limited, Orion Corporation, Nephron Pharmaceuticals Corporation, Curia Global Inc., Kindeva Drug Delivery L.P., Minakem SAS, Axplora Group GmbH, Cosmo Pharmaceuticals N.V., Manus Aktteva Biopharma LLP, Tovec Pharma Pvt. Ltd., Nutra Respiro Healthcare Pvt. Ltd.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/budesonide-inhaler-global-market-report

How Do Regional Market Performances Compare Within The Budesonide Inhaler Industry?

North America was the largest region in the budesonide inhaler market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the budesonide inhaler market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Budesonide Inhaler Market Report:

https://www.thebusinessresearchcompany.com/customise?id=24181&type=smp

Browse Through More Reports Similar to the Global Budesonide Inhaler Market 2025, By The Business Research Company

Respiratory Inhaler Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/respiratory-inhaler-devices-global-market-report

Dry Powder Inhaler Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/dry-powder-inhaler-global-market-report

Smart Inhalers Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/smart-inhalers-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795